RQ Bio

Private

#Infectious Disease #Antiviral Antibodies #Passive Immunization

RQ Bio is a UK-based biotechnology company developing a portfolio of virus-targeting monoclonal antibodies. The company emerged from research at the Rosalind Franklin Institute and raised a $115M Series A in 2026 to advance its preclinical pipeline of broadly neutralizing antibodies against viral pathogens.

Company Info

Sector:Biotechnology / Infectious Disease / Monoclonal Antibodies

Headquarters:Oxford, United Kingdom

Founded:2021

Website:www.rqbiotechnology.com/

Clinical Development Pipeline

Undisclosed virus-targeting mAb portfolio

Target: Broadly neutralizing antibodies

Multiple viral infections (preclinical)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

UK biotech secures $115M to advance portfolio of virus-targeting antibodies ↗

RQ Bio has clinched $115 million in a Series A raise to advance a preclinical pipeline of virus-targeting antibodies.

Leadership Team

Paul Kellam

Chief Scientific Officer

Špela Binter

Head of Immunology

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →